U.S. FDA approves Durata's acute bacterial skin infection drug

May 23, 2014 8:27 PM

15 0

WASHINGTON (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved a new drug to treat acute bacterial skin infections made by Durata Therapeutics Inc.

Approval of the drug, Dalvance, follows a positive recommendation by the FDA's advisory committee, which also gave a favorable review to a rival product from Cubist Pharmaceuticals Inc. The FDA is set to rule on the Cubist drug shortly.

Read more

To category page